Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2427752 | 1.00 | KDM4E (0.33) | KDM4EALDH1A1HTTATMTSHR | |
| SCHEMBL2433831 | 0.88 | POLB (0.32) | KDM4EALDH1A1HTTATMKMT2A | |
| SCHEMBL2433828 | 0.88 | POLB (0.32) | KDM4EALDH1A1HTTATMKMT2A | |
| SCHEMBL2434814 | 0.88 | KDM4E (0.32) | KDM4EALDH1A1HTTATMTP53 | |
| SCHEMBL2434817 | 0.88 | KDM4E (0.32) | KDM4EALDH1A1HTTATMTP53 | |
| SCHEMBL4139437 | 0.87 | KDM4E (0.36) | KDM4EALDH1A1HTTATMTSHR | |
| SCHEMBL4152499 | 0.87 | NR1I2 (0.38) | — | |
| SCHEMBL4152502 | 0.87 | NR1I2 (0.38) | — | |
| SCHEMBL4796290 | 0.87 | KDM4E (0.31) | KDM4EALDH1A1HTTATMTP53 | |
| SCHEMBL4153891 | 0.87 | KDM4E (0.31) | KDM4EHTTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140065103-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-06 | — | — | US | disclosed |
| EP-2086966-B1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20090274655-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION | 2009-11-05 | — | — | US | disclosed |
| EP-2086966-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SmithKline Beecham Corporation (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20090136448-A1 | Antiviral 2-Carboxy-Thiophene Compounds | CORFIELD JOHN ANDREW | 2009-05-28 | — | — | US | disclosed |
| WO-2009000818-A1 | 3-CARBONYLAMINOTHIOPHENE-2-CARBOXYLIC ACIDS AS HEPATITIS C VIRUS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009000818-A1 | 3-CARBONYLAMINOTHIOPHENE-2-CARBOXYLIC ACIDS AS HEPATITIS C VIRUS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-31 | — | — | WO | disclosed |
| WO-2008125599-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008125599-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-23 | — | — | WO | disclosed |
| EP-1971599-A1 | ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2008059042-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2007071434-A1 | ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274655-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | EIF2AK2, HAVCR2, GTF3C2 | KDM4E 1120/4885ALDH1A1 860/4885HTT 3128/4885 |
| US-20090136448-A1 | Antiviral 2-Carboxy-Thiophene Compounds | EIF2AK2, HAVCR2, MAVS | KDM4E 794/4885ALDH1A1 1037/4885HTT 3552/4885 |
| US-20140065103-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRIDAE VIRAL INFECTIONS | GOT1, RNASE1, SLC10A1 | KDM4E 4110/4885ALDH1A1 276/4885HTT 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.